ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Quick facts

Phase 2 pipeline

• ARQ 092 · Oncology
  ARQ 092 is a potent and selective inhibitor of mTORC1/2.
• ARQ 197 plus erlotinib · Oncology
  ARQ 197 is a small molecule inhibitor of c-MET, and when combined with erlotinib, targets the EGFR and c-MET pathways.
• ARQ 501 · Oncology
  ARQ 501 is a selective inhibitor of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase.
• ARQ 501 in combination with gemcitabine
• Pemetrexed, docetaxel or gemcitabine

Phase 1 pipeline

• Anti-Cancer Combination Therapy

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) portfolio CI brief
• ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) pipeline updates RSS

Related

• Sector hub: All tracked pharma companies